CY1113104T1 - Νεα σκευασματα εμβολιων - Google Patents

Νεα σκευασματα εμβολιων

Info

Publication number
CY1113104T1
CY1113104T1 CY20121100814T CY121100814T CY1113104T1 CY 1113104 T1 CY1113104 T1 CY 1113104T1 CY 20121100814 T CY20121100814 T CY 20121100814T CY 121100814 T CY121100814 T CY 121100814T CY 1113104 T1 CY1113104 T1 CY 1113104T1
Authority
CY
Cyprus
Prior art keywords
oil
present
water
nonionic
oav
Prior art date
Application number
CY20121100814T
Other languages
English (en)
Inventor
Alexis Guy Andre Parisot
Stephanie Marie-Catherine Desgouilles-Blechet
Catherine Charreyre
Claude Jean Marie Roulet
Original Assignee
Merial Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd. filed Critical Merial Ltd.
Publication of CY1113104T1 publication Critical patent/CY1113104T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Abstract

Η παρούσα εφεύρεση σχετίζεται με γαλακτώματα ελαίου σε νερό, με τη χρήση τους ως ανοσοενισχυτικά, και με φαρμακευτικές, ανοσολογικές συνθέσεις ή συνθέσεις εμβολίων που μπορούν να περιέχουν τα ίδια. Σε μια εφαρμογή, το γαλάκτωμα ελαίου σε νερό (OAV) μπορεί να περιέχει ένα υδατικό διάλυμα που περιέχει ένα ανοσογόνο, ένα ορυκτέλαιο, μια μη ιοντική λιπόφιλη αιθοξυλιωμένη λιπαρή αλκοόλη και ένα μη ιοντικό υδρόφιλο επιφανειοδραστικό μέσο. Σε μια άλλη εφαρμογή, το γαλάκτωμα ελαίου σε νερό (OAV) μπορεί να περιέχει ένα υδατικό διάλυμα που περιέχει ένα ανοσογόνο, ένα μη ιοντικό λιπόφιλο επιφανειοδραστικό μέσο, ένα ορυκτέλαιο και μια μη ιοντική υδρόφιλη αιθοξυλιωμένη αλκοόλη. Η παρούσα εφεύρεση επίσης περιλαμβάνει μια μέθοδο παρασκευής μιας σύνθεσης εμβολίου με χρήση του άνοσο ενισχυτικού της παρούσας εφεύρεσης, τη σύνθεση εμβολίου που λαμβάνεται με τον τρόπο αυτό και μεθόδους χρήσης.
CY20121100814T 2005-04-15 2012-09-10 Νεα σκευασματα εμβολιων CY1113104T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/107,000 US7691368B2 (en) 2005-04-15 2005-04-15 Vaccine formulations
EP06740939A EP1888107B1 (en) 2005-04-15 2006-04-13 Novel vaccine formulations

Publications (1)

Publication Number Publication Date
CY1113104T1 true CY1113104T1 (el) 2016-04-13

Family

ID=36950184

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100814T CY1113104T1 (el) 2005-04-15 2012-09-10 Νεα σκευασματα εμβολιων

Country Status (25)

Country Link
US (1) US7691368B2 (el)
EP (2) EP1888107B1 (el)
JP (1) JP5093902B2 (el)
KR (1) KR101292874B1 (el)
CN (1) CN101184501A (el)
AR (1) AR053360A1 (el)
AU (2) AU2006236711B2 (el)
BR (1) BRPI0610633B1 (el)
CA (1) CA2604432C (el)
CY (1) CY1113104T1 (el)
DK (1) DK1888107T3 (el)
ES (1) ES2389377T3 (el)
HK (1) HK1116085A1 (el)
IL (1) IL186600A (el)
MX (1) MX2007012785A (el)
MY (1) MY144189A (el)
NZ (2) NZ562663A (el)
PL (1) PL1888107T3 (el)
PT (1) PT1888107E (el)
RU (1) RU2422155C2 (el)
SI (1) SI1888107T1 (el)
TW (1) TWI376232B (el)
UA (1) UA94404C2 (el)
WO (1) WO2006113373A2 (el)
ZA (1) ZA200708634B (el)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
KR101347503B1 (ko) * 2005-09-09 2014-01-02 인터벳 인터내셔널 비.브이. Ｐｃｖ-2 백신
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
JP2009514850A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
ES2792398T3 (es) 2005-11-04 2020-11-11 Seqirus Uk Ltd Vacunas adyuvantadas con antígenos de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
MX338626B (es) 2005-12-29 2016-04-26 Boehringer Ingelheim Vetmed Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
TWI528970B (zh) * 2005-12-29 2016-04-11 百靈佳殷格翰家畜藥品公司 多價第二型豬環狀病毒（ｐｃｖ２）免疫組合物及製備該組合物之方法
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
KR20080100384A (ko) * 2006-03-03 2008-11-17 메리얼 리미티드 마이코플라즈마 하이오뉴모니아에 백신
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US20100010199A1 (en) 2006-09-11 2010-01-14 Novartis Ag Making influenza virus vaccines without using eggs
US20100136060A1 (en) * 2006-11-22 2010-06-03 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
WO2008068631A2 (en) 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
US20100129397A1 (en) 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
PT2481420T (pt) * 2006-12-15 2019-05-31 Boehringer Ingelheim Animal Health Usa Inc Vacina para porcos anti-pcv2 de dose única
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
KR20150082667A (ko) 2007-04-06 2015-07-15 인비라젠 인코포레이티드 살아있는 약독화된 바이러스를 위한 방법 및 조성물
PL2185191T3 (pl) 2007-06-27 2013-02-28 Novartis Ag Szczepionki przeciwko grypie o małej zawartości dodatków
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CN101951949B (zh) 2007-10-19 2013-10-02 诺华股份有限公司 脑膜炎球菌疫苗制剂
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CN106562927A (zh) * 2007-12-21 2017-04-19 硕腾服务有限责任公司 经热处理的菌苗，及由这些经热处理的菌苗制备的乳剂疫苗
WO2009088950A2 (en) * 2007-12-31 2009-07-16 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 virus like particle with foreign amino acid insertion
CA2712006A1 (en) * 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
NZ587798A (en) 2008-03-18 2013-06-28 Novartis Ag Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
EP2306812A4 (en) * 2008-07-30 2013-02-20 Univ Kentucky Res Found EQUINE DISEASE MODEL FOR NEUROLOGICAL AUROPTIC VIRUS DISEASE AND USED ASSAYS
AU2009294318B2 (en) 2008-09-18 2014-04-24 Novartis Ag Vaccine adjuvant combinations
EP2367566B2 (en) 2008-11-28 2019-11-27 Boehringer Ingelheim Animal Health USA Inc. Recombinant avian influenza vaccine and uses thereof
US20120093860A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
AU2010212547B2 (en) 2009-02-10 2015-03-12 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
JP2012519482A (ja) 2009-03-06 2012-08-30 ノバルティス アーゲー クラミジア抗原
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
JP5668049B2 (ja) 2009-03-24 2015-02-12 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
JP5744852B2 (ja) * 2009-05-19 2015-07-08 バイオプロパティーズ ピーティーワイ リミテッド Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅの温度感受性ワクチン株およびその使用
KR101800245B1 (ko) 2009-05-21 2017-11-22 노파르티스 아게 비-내인성 ｐｏｌ ｉ 프로모터를 사용하는 역 유전학
JP5823379B2 (ja) 2009-05-29 2015-11-25 ノバルティス アーゲー インフルエンザウイルスヘマグルチニンについてのアッセイ
EP2451833B1 (en) 2009-07-07 2018-01-17 GlaxoSmithKline Biologicals SA Conserved escherichia coli immunogens
EP2464658B1 (en) 2009-07-16 2014-10-01 Novartis AG Detoxified escherichia coli immunogens
RU2558257C2 (ru) * 2009-07-31 2015-07-27 Нэшнл Рисерч Каунсл Оф Канада ВНЕШНИЙ КОРОВОЙ ЭПИТОП ЛИПОПОЛИСАХАРИДА Н. pylori
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
BR112012008338A2 (pt) 2009-09-10 2019-09-24 Novartis Ag combinação de vacinas contra doenças do trato respiratório.
CA2773486C (en) * 2009-09-10 2017-10-10 Merial Limited New vaccine formulations comprising saponin-containing adjuvants
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
EP2491117B2 (en) 2009-10-20 2017-06-28 Novartis AG Improved reverse genetics methods for virus rescue
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
CA2793510A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
FR2957933B1 (fr) * 2010-03-24 2012-04-27 Seppic Sa Vaccin vivant pour maladies aviaires
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2556151A1 (en) 2010-04-07 2013-02-13 Novartis AG Method for generating a parvovirus b19 virus-like particle
US9555093B2 (en) 2010-04-30 2017-01-31 Temasek Life Sciences Laboratory Limited Universal vaccine against H5N1 lineages
PL2569007T3 (pl) 2010-05-11 2016-04-29 Intervet Int Bv Szczepionka przeciwko Mycoplasma Hyopneumoniae, odpowiednia do podawania w obecności przeciwciał pochodzących od matki
CN103025350A (zh) 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
EP3153578A1 (en) 2010-07-06 2017-04-12 Novartis Ag Norovirus derived immunogenic compositions and methods
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
TR201811280T4 (tr) 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Düşük antijen ve/ veya adjuvan dozları olan karma aşılar.
EP2736921B1 (en) 2011-07-25 2018-06-27 GlaxoSmithKline Biologicals SA Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
ES2732708T3 (es) 2011-09-14 2019-11-25 Glaxosmithkline Biologicals Sa Procedimientos de fabricación de glucoconjugados de sacárido-proteína
EP2768528A1 (en) 2011-10-20 2014-08-27 Novartis AG Adjuvanted influenza b virus vaccines for pediatric priming
WO2013088367A1 (en) 2011-12-12 2013-06-20 Novartis Ag Assay for influenza virus hemagglutinins
CN104023744A (zh) 2011-12-23 2014-09-03 诺华股份有限公司 用于针对金黄色葡萄球菌免疫的稳定组合物
AU2013221479B2 (en) * 2012-02-14 2017-06-08 Boehringer Ingelheim Animal Health USA Inc. Rotavirus subunit vaccines and methods of making and use thereof
AU2013205478B9 (en) 2012-03-02 2014-11-20 Seqirus UK Limited Influenza virus reassortment
JP2015526062A (ja) 2012-06-04 2015-09-10 ノバルティス アーゲー 改善された安全性試験
US20150203543A1 (en) 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
EP2890394B1 (en) 2012-08-31 2019-05-01 GlaxoSmithKline Biologicals SA Stabilised proteins for immunising against staphylococcus aureus
WO2014039978A2 (en) 2012-09-10 2014-03-13 Szathmary Dr Susan Vaccine to prevent mycoplasmal infection in waterfowl
CA2882382A1 (en) 2012-09-18 2014-03-27 Novartis Ag Outer membrane vesicles
EA201590427A1 (ru) 2012-10-02 2015-09-30 Глаксосмитклайн Байолоджикалс С.А. Нелинейные сахаридные конъюгаты
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
AU2013351182C1 (en) 2012-11-30 2018-11-08 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
WO2014086732A2 (en) 2012-12-03 2014-06-12 Novartis Ag Influenza virus reassortment
BR112015021880A2 (pt) 2013-03-13 2017-09-26 Novartis Ag rearranjo de vírus influenza b
ES2882374T3 (es) 2013-05-08 2021-12-01 Pharmgate Biologics Inc Vacuna para PCV2 y micoplasma
CN105828835A (zh) 2013-05-10 2016-08-03 诺华股份有限公司 避免流感疫苗中的发作性嗜睡病风险
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
AU2014276418A1 (en) 2013-06-06 2016-01-21 Novartis Ag Influenza virus reassortment
AU2014329524B2 (en) 2013-10-02 2019-01-17 Boehringer Ingelheim Animal Health USA Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
CA2931137C (en) * 2013-12-03 2023-03-14 Intervet International B.V. Vaccine against porcine circo virus type 2
CN103751779A (zh) * 2014-02-25 2014-04-30 中国农业科学院上海兽医研究所 O型口蹄疫多肽的泊洛沙姆凝胶佐剂
EA037818B1 (ru) 2014-03-26 2021-05-25 Глаксосмитклайн Байолоджикалс С.А. Мутантные стафилококковые антигены
US9713639B2 (en) 2014-05-19 2017-07-25 Merial, Inc. Recombinant spike protein subunit based vaccine for porcine epidemic diarrhea virus (PEDV)
US20150359880A1 (en) * 2014-06-16 2015-12-17 Biomune Company Dual adjuvant vaccine compositions, preparation and uses
CN105267962A (zh) * 2014-06-18 2016-01-27 潘皓 纳米乳疫苗辅剂
JP2015120709A (ja) * 2015-01-09 2015-07-02 ラボラトリオ アヴィメキシコ エスエー ディーイー シーヴィーＬａｂｏｒａｔｏｒｉｏ Ａｖｉ−Ｍｅｘ，Ｓ．Ａ． Ｄｅ Ｃ．Ｖ． 遺伝子組み換え不活性化ウィルスベクターワクチン
WO2016210083A2 (en) 2015-06-26 2016-12-29 Merial, Inc. Inactivated canine influenza vaccines and methods of making and uses thereof
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
KR102576962B1 (ko) 2015-07-07 2023-09-11 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
JP6986019B2 (ja) 2015-10-08 2021-12-22 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド レプトスピラ用生弱毒化異種ワクチン
MA49414A (fr) 2015-11-23 2020-04-22 Boehringer Ingelheim Animal Health Usa Inc Protéines de fusion de dmdv et e2 et leurs utilisations
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
JOP20190088A1 (ar) 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
JP7174698B2 (ja) * 2016-11-29 2022-11-17 インターベット インターナショナル ベー． フェー． ブタワクチン
EP4112072A1 (en) 2016-12-14 2023-01-04 Boehringer Ingelheim Animal Health USA Inc. Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them
FR3092754B1 (fr) * 2019-02-18 2022-06-03 Total Marketing Services Composition adjuvante pour vaccin
US20230000971A1 (en) 2019-11-18 2023-01-05 Seqirus Pty Ltd. Method for producing reassortant influenza viruses
CN113546162B (zh) * 2021-05-31 2023-07-18 江苏省农业科学院 一种支原体疫苗及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250289A (en) * 1987-07-24 1993-10-05 The Boots Company Plc Sunscreen compositions
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
PL155558B1 (pl) * 1988-01-28 1991-12-31 Inst Ciezkiej Syntezy Orga Sposób wytwarzania kompozycji emulgującej
AU657907B2 (en) 1990-05-29 1995-03-30 Wyeth Holdings Corporation Mycoplasma hyopneumoniae vaccine
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
DE69426228T2 (de) 1993-02-08 2001-03-01 Bayer Ag Verfahren zum Vermehren des das Reproduktions- und Atemwegs-Syndrom verursachenden Schweinevirus und dessen Verwendung als Impfstoff.
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US5985177A (en) 1995-12-14 1999-11-16 Shiseido Co., Ltd. O/W/O type multiple emulsion and method of preparing the same
US5866401A (en) 1996-03-01 1999-02-02 Schering Corporation Porcine reproductive and respiratory syndrome vaccine
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US7371395B2 (en) 2003-07-24 2008-05-13 Merial Limited Vaccine formulations
US9390965B2 (en) 2013-12-20 2016-07-12 Taiwan Semiconductor Manufacturing Co., Ltd. Air-gap forming techniques for interconnect structures

Also Published As

Publication number Publication date
AR053360A1 (es) 2007-05-02
CA2604432C (en) 2013-06-11
CN101184501A (zh) 2008-05-21
US7691368B2 (en) 2010-04-06
EP1888107B1 (en) 2012-06-13
HK1116085A1 (en) 2008-12-19
SI1888107T1 (sl) 2012-09-28
NZ584420A (en) 2011-11-25
DK1888107T3 (da) 2012-07-23
WO2006113373A3 (en) 2007-02-01
EP1888107A2 (en) 2008-02-20
PL1888107T3 (pl) 2012-11-30
ZA200708634B (en) 2008-10-29
JP5093902B2 (ja) 2012-12-12
US20060233831A1 (en) 2006-10-19
WO2006113373A2 (en) 2006-10-26
JP2008536860A (ja) 2008-09-11
ES2389377T3 (es) 2012-10-25
UA94404C2 (ru) 2011-05-10
RU2422155C2 (ru) 2011-06-27
EP2422809A1 (en) 2012-02-29
AU2010206041B2 (en) 2012-08-02
MX2007012785A (es) 2008-01-11
CA2604432A1 (en) 2006-10-26
AU2006236711B2 (en) 2010-07-29
RU2007142202A (ru) 2009-05-20
IL186600A0 (en) 2008-01-20
IL186600A (en) 2014-05-28
KR20070122550A (ko) 2007-12-31
AU2006236711A1 (en) 2006-10-26
NZ562663A (en) 2010-04-30
AU2010206041A1 (en) 2010-08-19
BRPI0610633A2 (pt) 2010-07-13
TW200716165A (en) 2007-05-01
KR101292874B1 (ko) 2013-08-05
BRPI0610633B1 (pt) 2021-07-20
MY144189A (en) 2011-08-15
TWI376232B (en) 2012-11-11
PT1888107E (pt) 2012-07-26

Similar Documents

Publication Publication Date Title
CY1113104T1 (el) Νεα σκευασματα εμβολιων
CY1108994T1 (el) Θερμοαναστρεψιμο ανοσοενισχυτικο γαλακτωμα
CY1117874T1 (el) Χρηση ενος ιου γριπης και ενος ανοσοενισχυτικου γαλακτωματος ελαιου-σε-νερο για την προκλιση αποκρισης των cd4 τ-κυτταρων και/ή βελτιωμενη αποκριση των β-κυτταρων μνημης
CY1113546T1 (el) Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CR10555A (es) Vacunas para malaria
CY1121420T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
UY27840A1 (es) Vacunas
NO20023829L (no) Proteosom influensavaksine
BR112022014830A2 (pt) Formulações de vacina para coronavírus
Fox et al. TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses
PE20110642A1 (es) Formulaciones antifungicas topicas a base de terbinafina y compuestos similares a terbinafina y metodos de uso
AR067087A1 (es) Composicion de vacuna y metodo para elaborarla
BR112018072248A2 (pt) composições e métodos relacionados a imunógenos contra hiv-1
DOP2010000056A (es) Un antigeno de malaria para vacunar contra la malaria
Abhyankar et al. Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica
CO6290701A2 (es) Vacuna de vih que comprende una proteina de fusion y un agente estabilizador
Lisk et al. Toll-like receptor ligand based adjuvant, PorB, increases antigen deposition on germinal center follicular dendritic cells while enhancing the follicular dendritic cells network
BR112023019301A2 (pt) Formulações de vacina de coronavírus
AR059648A1 (es) Antigenos vacunales quimericos contra el virus de la peste porcina clasica
SE0000730D0 (sv) Lipid carrier
UY32930A (es) Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas
BR0314937A (pt) Composições imunogênicas de patógenos intracelulares recombinantes e métodos para uso
NO20060395L (no) Antigenholdig dyrevaksine
UY39202A (es) Composición de prometrina en forma de micro emulsión